Literature DB >> 21429552

Synthesis of sulfanilamide derivatives and investigation of in vitro inhibitory activities and antimicrobial and physical properties.

Hasan Turkmen1, Gulay Zengin, Belkis Buyukkircali.   

Abstract

Novel sulfanilamide derivatives were synthesized and evaluated for carbonic anhydrase inhibitory activity as a target for the treatment of glaucoma, and antibacterial properties for use in chemotherapy. Synthesized compounds were characterized by FT-IR, (1)H NMR, (13)C NMR and photoluminescence. In vitro inhibitory activities were measured by UV-Vis and some of the compounds were found have greater inhibitory effects than the lead compound sulfanilamide. The correlation between inhibitory activity, biological properties and the physicochemical properties of water solubility and partition coefficients was also investigated. Sulfanilamide derivatives gave intense emissions upon irradiation by UV light and a dimethyl substituted compound and a cyclic analog have photoluminescence quantum yields 42% and 31% and long excited-state lifetimes of 3.92 and 2.91 ns, respectively.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21429552     DOI: 10.1016/j.bioorg.2011.02.004

Source DB:  PubMed          Journal:  Bioorg Chem        ISSN: 0045-2068            Impact factor:   5.275


  3 in total

Review 1.  Pharmaceutical and medicinal significance of sulfur (SVI)-Containing motifs for drug discovery: A critical review.

Authors:  Chuang Zhao; K P Rakesh; L Ravidar; Wan-Yin Fang; Hua-Li Qin
Journal:  Eur J Med Chem       Date:  2018-11-22       Impact factor: 6.514

2.  4-(3-Chloro-2,2-dimethyl-propanamido)-benzene-sulfonamide.

Authors:  Serife Pınar Yalçın; Mehmet Akkurt; Mustafa Durgun; Baki Türkkan; Hasan Türkmen
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2012-11-24

3.  4-(5-Chloro-penta-namido)-benzene-sulfonamide.

Authors:  Hasan Türkmen; Serife Pınar Yalçın; Mehmet Akkurt; Mustafa Durgun
Journal:  Acta Crystallogr Sect E Struct Rep Online       Date:  2012-11-28
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.